Key points are not available for this paper at this time.
These findings suggest that thalamic atrophy is a clinically relevant biomarker of the neurodegenerative disease process in multiple sclerosis.
Share your take
Add a clinician perspective alongside expert commentary.
Houtchens et al. (Mon,) studied this question.